Harrow Health Stock Alpha and Beta Analysis
| HROW Stock | USD 42.90 0.98 2.23% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Harrow Health. It also helps investors analyze the systematic and unsystematic risks associated with investing in Harrow Health over a specified time horizon. Remember, high Harrow Health's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Harrow Health's market risk premium analysis include:
Beta 1.98 | Alpha (0.10) | Risk 4.21 | Sharpe Ratio 0.0172 | Expected Return 0.0722 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Harrow |
Harrow Health Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Harrow Health market risk premium is the additional return an investor will receive from holding Harrow Health long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Harrow Health. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Harrow Health's performance over market.| α | -0.1 | β | 1.98 |
Harrow Health expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Harrow Health's Buy-and-hold return. Our buy-and-hold chart shows how Harrow Health performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Harrow Health Market Price Analysis
Market price analysis indicators help investors to evaluate how Harrow Health stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Harrow Health shares will generate the highest return on investment. By understating and applying Harrow Health stock market price indicators, traders can identify Harrow Health position entry and exit signals to maximize returns.
Harrow Health Return and Market Media
The median price of Harrow Health for the period between Tue, Aug 27, 2024 and Mon, Nov 25, 2024 is 45.14 with a coefficient of variation of 11.14. The daily time series for the period is distributed with a sample standard deviation of 5.15, arithmetic mean of 46.22, and mean deviation of 4.25. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 150000 shares by Baum Mark L of Harrow Health subject to Rule 16b-3 | 08/30/2024 |
2 | Harrow Health Unveils Performance Strategy to Investors - TipRanks | 09/09/2024 |
3 | Disposition of 90000 shares by Saharek John P. of Harrow Health at 7.37 subject to Rule 16b-3 | 09/11/2024 |
4 | Acquisition by Opaleye Management Inc. of 10000 shares of Harrow Health at 6.7632 subject to Rule 16b-3 | 09/13/2024 |
5 | Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in ... | 10/10/2024 |
6 | Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024 | 10/31/2024 |
7 | Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrows Branded Eyecare Products | 11/07/2024 |
8 | Harrow is on the Move, Heres Why the Trend Could be Sustainable | 11/08/2024 |
9 | Cisco, Cyberark, Suncor to report earnings Wednesday | 11/12/2024 |
10 | Harrow Inc Q3 2024 Earnings Report Preview What To Look For | 11/13/2024 |
11 | Harrow Inc Q3 2024 Earnings Revenue at 49.3M, Misses Estimate EPS Loss of 0. ... | 11/14/2024 |
12 | Harrow Inc Q3 2024 Earnings Call Highlights Record Revenue and Strategic Growth Amid ... | 11/15/2024 |
13 | Harrows ImprimisRx Subsidiary Receives 34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc. | 11/21/2024 |
14 | OSRX, Inc. Responds to Jury Verdict in Trademark Infringement Case | 11/22/2024 |
About Harrow Health Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Harrow or other stocks. Alpha measures the amount that position in Harrow Health has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Dividend Yield | 6.32E-4 | 6.0E-4 | Price To Sales Ratio | 2.81 | 2.67 |
Harrow Health Upcoming Company Events
As portrayed in its financial statements, the presentation of Harrow Health's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Harrow Health's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Harrow Health's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Harrow Health. Please utilize our Beneish M Score to check the likelihood of Harrow Health's management manipulating its earnings.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Harrow Health
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Harrow Stock Analysis
When running Harrow Health's price analysis, check to measure Harrow Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Harrow Health is operating at the current time. Most of Harrow Health's value examination focuses on studying past and present price action to predict the probability of Harrow Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Harrow Health's price. Additionally, you may evaluate how the addition of Harrow Health to your portfolios can decrease your overall portfolio volatility.